DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at Leerink Swann cut their Q1 2019 earnings per share (EPS) estimates for DexCom in a research note issued on Wednesday. Leerink Swann analyst D. Antalffy now expects that the medical device company will post earnings of ($0.03) per share for the quarter, down from their previous forecast of $0.03. Leerink Swann also issued estimates for DexCom’s Q2 2019 earnings at ($0.02) EPS, Q3 2019 earnings at ($0.01) EPS, Q4 2019 earnings at $0.01 EPS, FY2019 earnings at ($0.05) EPS and FY2020 earnings at $0.35 EPS.

How to Become a New Pot Stock Millionaire

A number of other analysts have also recently issued reports on DXCM. Piper Jaffray Companies set a $78.00 price objective on DexCom and gave the company a “buy” rating in a research report on Friday. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and set a $58.00 price objective for the company in a research report on Friday. Zacks Investment Research raised DexCom from a “sell” rating to a “hold” rating in a research report on Friday, March 16th. ValuEngine cut DexCom from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Finally, BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $67.03.

Shares of DexCom (NASDAQ:DXCM) traded up $3.57 during mid-day trading on Friday, hitting $70.31. The stock had a trading volume of 899,053 shares, compared to its average volume of 1,215,985. DexCom has a twelve month low of $42.62 and a twelve month high of $86.32. The company has a quick ratio of 5.04, a current ratio of 5.36 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $5,890.58, a P/E ratio of -118.85 and a beta of 0.27.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. DexCom had a negative return on equity of 13.99% and a negative net margin of 6.99%. The business had revenue of $221.00 million for the quarter, compared to the consensus estimate of $217.82 million.

Several institutional investors have recently bought and sold shares of DXCM. American International Group Inc. bought a new position in DexCom during the 4th quarter worth about $116,000. Thompson Davis & CO. Inc. bought a new position in DexCom in the fourth quarter valued at approximately $137,000. Zions Bancorporation increased its stake in DexCom by 36,222.2% in the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after acquiring an additional 3,260 shares during the last quarter. Toronto Dominion Bank increased its stake in DexCom by 251.0% in the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock valued at $178,000 after acquiring an additional 2,608 shares during the last quarter. Finally, Marco Investment Management LLC bought a new position in DexCom in the fourth quarter valued at approximately $201,000.

In other news, EVP Richard Doubleday sold 1,638 shares of DexCom stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $56.32, for a total value of $92,252.16. Following the transaction, the executive vice president now directly owns 65,049 shares in the company, valued at $3,663,559.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terrance H. Gregg sold 10,000 shares of DexCom stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the completion of the transaction, the insider now owns 484,559 shares in the company, valued at $27,552,024.74. The disclosure for this sale can be found here. Insiders sold 34,908 shares of company stock worth $2,056,635 over the last quarter. 1.70% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: “Brokers Issue Forecasts for DexCom, Inc.’s Q1 2019 Earnings (DXCM)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/brokers-issue-forecasts-for-dexcom-inc-s-q1-2019-earnings-dxcm/1960473.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.